other material
confidence high
sentiment neutral
materiality 0.25
Elevance reaffirms FY2026 EPS guidance: at least $20.10 GAAP, $27.00 adjusted
Elevance Health, Inc.
- Reaffirms FY2026 shareholders' EPS guidance of at least $20.10, including ~$6.90 net unfavorable items.
- Excluding items, adjusted shareholders' EPS guidance at least $27.00 per diluted share.
- Reaffirms FY2026 benefit expense ratio guidance of 90.2% ± 50 basis points.
- Guidance reaffirmed during investor meetings over the next several weeks.